• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Biolex Therapeutics, Inc. - Product Pipeline Review - Q4 2010 - Product Image

Biolex Therapeutics, Inc. - Product Pipeline Review - Q4 2010

  • ID: 1446805
  • November 2010
  • 54 pages
  • Global Markets Direct

Biolex Therapeutics, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Biolex Therapeutics, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Biolex Therapeutics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Biolex Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Biolex Therapeutics, Inc. Snapshot
Biolex Therapeutics, Inc. Overview
Key Information
Key Facts
Biolex Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Biolex Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Biolex Therapeutics, Inc. – Pipeline Products Glance
Biolex Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Biolex Therapeutics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Biolex Therapeutics, Inc. – Drug Profiles
Locteron
Product Description
Mechanism of Action
R&D Progress
BLX-155
Product Description
Mechanism of Action
R&D Progress
BLX-301
Product Description
Mechanism of Action
R&D Progress
Biolex Therapeutics, Inc. – Pipeline Analysis
Biolex Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Biolex Therapeutics, Inc. Pipeline Products By Target
Biolex Therapeutics, Inc. – Pipeline Products by Route of Administration
Biolex Therapeutics, Inc. – Pipeline Products by Molecule Type
Biolex Therapeutics, Inc. – Recent Pipeline Updates
Biolex Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 28, 2010: Biolex Announces Positive Phase IIb Results Of Locteron For Treatment Of Hepatitis C Infection
Apr 18, 2010: OctoPlus' Licensee Biolex Therapeutics To Present Phase IIb Data Of Locteron At International Liver Congress
Apr 16, 2010: Biolex Presents Interim Results From EMPOWER Phase IIb Study Of Locteron In Chronic Hepatitis C At EASL
Apr 16, 2010: Biolex Presents Interim Results From EMPOWER Phase IIb Study Of Locteron In Chronic Hepatitis C At EASL
Apr 15, 2010: Biolex Announces Presentation Of Interim Results From Select-2 Phase IIb Trial Of Locteron In Chronic Hepatitis C
Jul 16, 2009: Biolex Announces Oral Presentation Of Preclinical Results for Direct-Acting Thrombolytic BLX-155 At ISTH Meeting
Jun 22, 2009: Biolex Therapeutics Announces Completion Of Patient Enrollment In The SELECT-2 Phase IIb Trial Of Locteron
Apr 24, 2009: Biolex Therapeutics Presents Phase Iia Clinical Trial Results Of Locteron
Apr 20, 2009: Biolex Therapeutics Commences Patient Dosing In The SELECT-2 Phase IIb Trial Of Locteron
Apr 24, 2008: Biolex Therapeutics Present Locteron Phase IIa Results At EASL Conference
Financial Deals Landscape
Biolex Therapeutics, Inc., Deals Volume Summary, 2004 to YTD 2010
Biolex Therapeutics, Inc., Deals Summary By Region, 2004 to YTD 2010
Biolex Therapeutics, Inc., Deals Summary, 2004 to YTD 2010
Biolex Therapeutics, Inc. Detailed Deal Summary
Acquisition
Biolex Therapeutics Acquires LemnaGene
Biolex Acquires Epicyte Pharmaceutical
Venture Financing
Biolex Therapeutics Secures $60 Million In Series D Financing
Biolex Therapeutics Secures $30 Million In Series C Financing
Biolex Therapeutics Secures $36 Million In Series B Financing
Equity Offering
Clinica Baviera Completes Initial Public Offering Of $174 Million
MRC Technology Enters Into Co-Development Agreement With Biolex Therapeutics
Biolex Therapeutics Expands Co-Development Agreement With Medarex
Biolex Enters Into Collaboration With Centocor
Biolex Enters Into Collaboration With Octoplus
Biolex Therapeutics Enters Into Agreement With Medarex
Biolex Expands Collaboration Agreement With Centocor
Biolex Expands Collaboration Agreement With Centocor
Licensing Agreements
Biolex Therapeutics Enters Into Agreement With Octoplus
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS